Note: Descriptions are shown in the official language in which they were submitted.
CA 2794006 2017-05-12
(20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1a,25-
DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-
DIMETHYL-1a,25-HYDROXYVITAMIN D3
FIELD
[0002] This present technology relates to vitamin D compounds, and more
particularly to (20S)-2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3
and
(20R)- 2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 and
derivatives thereof,
and to pharmaceutical formulations that include this compound. The present
technology also
relates to the use of these compounds in the treatment of various diseases and
in the
preparation of medicaments for use in treating various diseases.
BACKGROUND
[0003] The natural hormone, la,25-dihydroxyvitamin D3 (also referred to as
la,25-
dihydroxycholecalciferol and calcitriol) and its analog in the ergosterol
series, i.e. la,25-
dihydroxyvitamin D2, are known to be highly potent regulators of calcium
homeostasis in
animals and humans, and their activity in cellular differentiation has also
been established,
Ostrem et al., Proc. Natl. Acad. Sci. USA, 84, 2610 (1987). Many structural
analogs of these
metabolites have been prepared and tested, including la-hydroxyvitamin D3, la-
hydroxyvitamin D2, various side chain homologated vitamins, and fluorinated
analogs. Some
of these compounds exhibit an interesting separation of activities in cell
differentiation and
calcium regulation. This difference in activity may be useful in the treatment
of a variety of
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
diseases such as renal osteodystrophy, vitamin D-resistant rickets,
osteoporosis, psoriasis, and
certain malignancies. The structure of 1a,25-dihydroxyvitamin D3 and the
numbering system
used to denote the carbon atoms in this compound are shown below.
22 24
21 26
,
18 ' 20 25
12
16 27 23 OH
17
11
13
14 e
9
8 15
6 7
19
4
3 1
HO\\ OH
2
la,25-Dihydroxyvitamin D3 = la,25-Dihydroxycholecalciferol = Calcitriol
SUMMARY
[0004] The present technology provides (20R)-2-methylene-19-nor-22-dimethyl-
1a,25-dihydroxyvitamin D3 and (20S)- 2-methylene-19-nor-22-dimethyl-la,25-
dihydroxyvitamin D3 and related compounds, pharmaceutical formulations that
include
(20S)-2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 or (20R)-2-
methylene-
19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3, methods of treating various
disease states
using this compound, and the use of this compound in the preparation of
medicaments for
treating various disease states.
[0005] Therefore, in one aspect, the present technology provides a compound
having
the formula T shown below:
2
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
Oe OX3
1
1
µos'
X10\\\ OX2
I
where X1, X2 and X/ may be the same or different and are independently
selected from H or
hydroxy-protecting groups. In some embodiments, the carbon at position 20 has
the S-
configuration as shown in the compound of formula IA and in others it has the
R-
configuration as shown in the compound of formula TB:
õ.
Oe ox3
Oe ox3
1 1
1 1
llexioe ox21 0`11
x o ox2
IA IB
3
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
[0006] In some embodiments of compounds of formulas I, IA, or IB, X1, X2
and X3
arc both hydroxy protecting groups such as silyl groups. In some such
embodiments, Xl and
X2 are both t-butyldimethylsily1 groups and X3 is a triethylsilyl group.
[0007] In some embodiments, the compound has the formula 11.
Iiii, OH
1
4.0µ'
HO' OH
II
[0008] In some embodiments, the compound is (20S)-2-methylene-19-nor-22-
dimethy1-1a,25-dihydroxyvitamin DI having the formula IIA as shown below or
the
compound is (20R)-2-methylene-19-nor-22-dimethy1-1a,25-dihydroxyvitamin D3
having the
formula JIB as shown below:
5 OH
Oe OH
1 1
1 1
110
0,,,
\µ`µ
HOµµ
OH HO\ OH
IIA IIB
4
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
[0009] In some embodiments, the compound of formula IIA is a compound of
formula TIC (MET-1), and in other embodiments, the compound of formula JIB is
a
compound of formula 11D (MET-2) and have the structures shown below:
OH
Oe OH
1 1
1 1
HO'" lel HOµl.
OH OH
=
IIC IID
[0010] Compounds of the present technology show a highly advantageous
pattern of
biological activity, including strong binding to the vitamin D receptor,
strong cell
differentiation and induction of 24-hydroxylase activity, yet low to very low
calcemic
activity. Thus the present compounds may be used in methods of treating a
subject suffering
from certain biological conditions. The methods include administering an
effective amount
of a compound of the present technology to the subject, wherein the biological
condition is
selected from psoriasis; leukemia; colon cancer; breast cancer; prostate
cancer; multiple
sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of
organ transplants;
an inflammatory disease selected from rheumatoid arthritis, asthma, or
inflammatory bowel
diseases; a skin condition selected from wrinkles, lack of adequate skin
firmness, lack of
adequate dermal hydration, or insufficient sebum secretion.
[0011] A compound of the present technology may be present in a composition
to
treat the above-noted diseases and disorders in an effective amount and
optionally including a
pharmaceutically acceptable carrier. In some embodiments, the amount of
compound
includes from about 0.01 lag per gram of composition to about 1 mg per gram of
the
composition, preferably from about 0.1 lug per gram to about 500 jig per gram
of the
composition, and may be administered topically, transdermally, orally, or
parenterally in
5
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
dosages of from about 0.01 ug per day to about 1 mg per day, preferably from
about 0.1 ug
per day to about 500 lug per day.
[0012] Further features and advantages of the present technology will be
apparent
from the following detailed description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figures 1-5 illustrate various biological activities of (20S)-2-
methylene-19-
nor-22-dimethyl-la,25-dihydroxyvitamin D3 (referred to as "MET-1" in the
figures)
compared with those of the native hormone 1a,25-dihydroxyvitamin D3 (referred
to as
"1,25(OH)2D3" in the figures). Figures 6-10 illustrate various biological
activities of (20R)-
2-methylene-19-nor-22-dimethyl-la,25-dihydroxyvitamin D3 (referred to as "MET-
2" in the
figures) compared with those of the native hormone, 1,25(OH)2D3.
[0014] Fig. 1 shows a graph of competitive binding to the nuclear vitamin D
hormone
receptor between MET-1 and the native hormone, 1,25(OH)2D3. MET-1 binds to the
nuclear
vitamin D hormone receptor with the same affinity as 1,25(OH)2D3.
[0015] Fig. 2 is a graph comparing the percent HL-60 cell differentiation
as a function
of the concentration of MET-1 with that of 1,25(OH)2D3. MET-1 has the about
four times
the potency of 1,25(OH)2D3 in causing the differentiation of HL-60 cells into
monocytes.
[0016] Fig. 3 is a graph comparing the in vitro transcription activity of
MET-1 with
that of 1,25(OH)2D3. MET-1 is about ten times more potent than 1,25(OH)2D3 in
increasing
transcription of the 24-hydroxylase gene.
[0017] Fig. 4 is a bar graph comparing the bone calcium mobilization
activity of
MET-1 with that of 1,25(OH)2D3 in rat. MET-1 is approximately 20 times less
potent than
1,25(OH)1D3 in releasing bone calcium stores.
[0018] Fig. 5 is a bar graph comparing the intestinal calcium transport
activity of
MET-1 with that of 1,25(OH)2D3. MET-1 is less potent than 1,25(OH)2D3 in
promoting
active calcium transport in the rat gut.
6
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
[0019] Fig. 6 shows a graph of competitive binding to the nuclear vitamin D
hormone
receptor between MET-2 and the native hormone, 1,25(OH)2D3. MET-2 binds to the
nuclear
vitamin D hormone receptor with the same affinity as 1,25(OH)2D3.
[0020] Fig. 7 is a graph comparing the percent HL-60 cell differentiation
as a function
of the concentration of MET-2 with that of 1,25(OH)2D3. MET-2 has the about
three times
the potency of 1,25(OH)2D3 in causing the differentiation of HL-60 cells into
monocytes.
[0021] Fig. 8 is a graph comparing the in vitro transcription activity of
MET-2 with
that of 1,25(OH)2D3. MET-2 is about three times more potent than 1,25(OH)2D3
in
increasing transcription of the 24-hydroxylase gene.
[0022] Fig. 9 is a bar graph comparing the bone calcium mobilization
activity of
MET-2 with that of 1,25(OH)2D3 in rat. MET-2 is approximately 16 times less
potent than
1,25(OH)1133 in releasing bone calcium stores.
[0023] Fig. 10 is a bar graph comparing the intestinal calcium transport
activity of
MET-2 with that of 1,25(OH)2D3. MET-2 is less potent than 1,25(OH)2D3 in
promoting
active calcium transport in the rat gut.
DETAILED DESCRIPTION
[0024] (20S)-2-Methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 and
(20R)-2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 were
synthesized, and
tested, and found to be useful in treating a variety of biological conditions
as described
herein. Structurally, these compounds have the formulas HA and JIB as shown
below:
7
CA 2799006 2017-05-12
. .
44
5, OH
Oe OH
1
1 1
HO'' =
H 0µ0" '
OH OH
IIA JIB
[0025] Preparation of (20S)-2-methylene-19-nor-22-dimethyl-1a,25-
dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1a,25-
dihydroxyvitamin D3
can be accomplished by condensing an appropriate bicyclic Windaus-Grundmann
type ketone
(IIIA or IIIB) with the allylic phosphine oxide IV followed by deprotection
(removal of the
Y, Y1 and Y2 hydroxy protecting groups).
"Iõ,,,, OY OY1 CH2POPh2
SW" 11111111111 es'
Y2 0 0Y1
H H
0 0
IIIA IIIB IV
[0026] Hydraindanones of structure IIIA and IIIB can prepared by
slight modification
of known methods as will be readily apparent to one of skill in the art and
described herein.
Specific examples of methods used to synthesize bicyclic ketones for vitamin D
analogs are
those described in Mincione etal., Synth. Commun 19, 723, (1989); and Peterson
etal., J.
Org. Chem. 51, 1948, (1986). An overall process for synthesizing 2-alkylidene-
19-nor-
vitamin D compounds is illustrated and described in U.S. Patent No. 5,843,928.
8
CA 2794006 2017-05-12
[0027] In
phosphine oxide IV, Yi and Y2 are hydroxy-protecting groups such as silyl
protecting groups. The t-butyldimethylsilyl (TBDMS) group is an example of a
particularly
useful hydroxy-protecting group. The process described above represents an
application of
the convergent synthesis concept, which has been applied effectively to the
preparation of
numerous vitamin D compounds (see Lythgoe et al., J. Chem. Soc. Perkin Trans.
I, 590
(1978); Lythgoe, Chem. Soc. Rev. 9,449 (1983); Toh et al., J. Org. Chem. 48,
1414 (1983);
Baggiolini etal., J. Org. Chem. 5/, 3098 (1986); Sardina etal., J. Org. Chem.
51, 1264
(1986); J. Org. Chem. 51, 1269 (1986); DeLuca etal., U.S. Patent No.
5,086,191; DeLuca et
al., U.S. Patent No. 5,536,713; and DeLuca etal., U.S. Patent No. 5,843,928.
9
CA 2794006 2017-05-12
Scheme 1
OH Me0 2 C/õ4õ. OH RuCI3 Me02C,,,,,,. OH
2 steps Na104
HO" OH 0s'
TBDMSO,kr OTBDMS TBDMS0\µ OTBDMS
OH OH 0
(-) Quinic Acid
A
MePh3P+ Br
n-BuLi
0
H0H2C/44õ. OH Me02C/õ4õ. OH
Na104 LAH
00µ' ,oss'
TBDMS& OTBDMS TBDMSON' OTBDMS TB DM S O OTBDMS
Me3SiCH2002Me
LDA
=
CO2Me CH2OH 2P(=0)Ph2
1. n-BuLi, TsCI
2. n-BuLi, PH
DIBALH 3. H202
õo=%s*
TBDMSe OTBDMS TBDMSO\ OTBDMS TBDMSCPO OTBDMS
[0028] Phosphine
oxide IV is a convenient reagent that may be prepared according to
the procedures described by Sicinski et al., J. Med. Chem., 41, 4662 (1998),
DeLuca et al.,
U.S. Patent No. 5,843,928; Perlman et al., Tetrahedron Lett. 32, 7663 (1991);
and DeLuca et
al., U.S. Patent No. 5,086,191. Scheme 1 shows the general procedure for
synthesizing
phosphine oxide IV as outlined in U.S. Patent No. 5,843,928.
[0029] As used herein, the term "hydroxy-protecting group" signifies any
group
commonly used for the temporary protection of the hydroxy (-OH) functional
group, such as,
but not limited to, alkoxycarbonyl, acyl, alkylsilyl or alkylarylsilyl groups
(hereinafter
referred to simply as "sily1" groups), and alkoxyalkyl groups. Alkoxycarbonyl
protecting
CA 2794006 2017-05-12
groups are alkyl-O-00- groups such as methoxycarbonyl, ethoxycarbonyl,
propoxycarbonyl,
isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxyearbonyl,
benzyloxycarbonyl or allyloxycarbonyl. The term "acyl" signifies an alkanoyl
group of 1 to
6 carbons, in all of its isomeric fowls, or a carboxyalkanoyl group of 1 to 6
carbons, such as
an oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such
as benzoyl, or a
halo, nitro or alkyl substituted benzoyl group. Alkoxyalkyl protecting groups
are groups such
as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and
tetrahydropyranyl. Preferred silyl-protecting groups are trimethylsilyl,
triethylsilyl, t-
butyldimethylsilyl, dibutylmethylsilyl, diphenylmethylsilyl,
phenyldimethylsilyl, diphenyl-t-
butylsily1 and analogous alkylated silyl radicals. The term "aryl" specifies a
phenyl-, or an
alkyl-, nitro- or halo-substituted phenyl group. An extensive list of
protecting groups for the
hydroxy functionality may be found in Protective Groups in Organic Synthesis,
Greene,
T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999)
which can be
added or removed using the procedures set forth therein.
[0030] A "protected hydroxy" group is a hydroxy group derivatized or
protected by
any of the above groups commonly used for the temporary or permanent
protection of
hydroxy functional groups, e.g., the silyl, alkoxyalkyl, acyl or
alkoxycarbonyl groups, as
previously defined.
[0031] Compounds of the present technology exhibit desirable, and highly
advantageous, patterns of biological activity. These compounds are
characterized by
relatively high binding to vitamin D receptors (see Figs. 1 and 5) and high
activity in HL-60
differentiation, but very low ability to mobilize calcium from bone (see Figs.
4 and 9) and
relatively low intestinal calcium transport activity (see Figs. 5 and 10), as
compared to that of
la,25-dihydroxyvitamin D3. Hence, these compounds can be characterized as
having little, if
any, calcemic activity at the dosages that la,25-dihydroxyvitamin D3 displays
significant
calcemic activity. Thus, the may be useful as a therapy for suppression of
secondary
hyperparathyroidism type renal osteodystrophy.
[0032] The compounds of the present technology are also suited for
treatment and
prophylaxis of human disorders which are characterized by an imbalance in the
immune
system, e.g. in autoimmune diseases, including multiple sclerosis, lupus,
diabetes mellitus,
host versus graft reaction, and rejection of organ transplants; and
additionally for the
11
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
treatment of inflammatory diseases, such as rheumatoid arthritis, asthma, and
inflammatory
bowel diseases such as celiac disease, ulcerative colitis and Crohn's disease.
Acne, alopecia
and hypertension are other conditions which may be treated with the compounds
of the
present technology.
[0033] The above compounds are also characterized by cell differentiation
activity
either equal to or significantly higher than that of 1a,25(01-1)2 D3 (see
Figs. 2 and 7). Thus,
this compound also provides a therapeutic agent for the treatment of
psoriasis, or as an anti-
cancer agent, especially against leukemia, colon cancer, breast cancer and
prostate cancer. In
addition, due to its relatively high cell differentiation activity, this
compound provides a
therapeutic agent for the treatment of various skin conditions including
wrinkles, lack of
adequate dermal hydration, i.e. dry skin, lack of adequate skin firmness, i.e.
slack skin, and
insufficient sebum secretion. Use of this compound thus not only results in
moisturizing of
skin but also improves the barrier function of skin.
[0034] The compounds of the present technology may be used to prepare
pharmaceutical formulations or medicaments that include a compound of the
present
technology in combination with a pharmaceutically acceptable carrier. Such
pharmaceutical
formulations and medicaments may be used to treat various biological disorders
such as those
described herein. Methods for treating such disorders typically include
administering an
effective amount of the compound or an appropriate amount of a pharmaceutical
formulation
or a medicament that includes the compound to a subject suffering from the
biological
disorder. In some embodiments, the subject is a mammal. In some such
embodiments, the
mammal is selected from a rodent, a primate, a bovine, an equine, a canine, a
feline, an
ursine, a porcine, a rabbit, or a guinea pig. In some such embodiments, the
mammal is a rat
or is a mouse. In some embodiments, the subject is a primate such as, in some
embodiments,
a human.
[0035] For treatment purposes, the compounds defined by formulas I, IA, IB,
II, IIA,
JIB, TIC, and IID may be formulated for pharmaceutical applications as a
solution in
innocuous solvents, or as an emulsion, suspension or dispersion in suitable
solvents or
carriers, or as pills, tablets or capsules, together with solid carriers,
according to conventional
methods known in the art. Any such formulations may also contain other
pharmaceutically
acceptable and non-toxic excipients such as stabilizers, anti-oxidants,
binders, coloring agents
or emulsifying or taste-modifying agents. Pharmaceutically acceptable
excipients and
12
CA 2794006 2017-05-12
carriers are generally known to those skilled in the art and are thus included
in the present
technology. Such excipients and carriers are described, for example, in
"Remingtons
Phaimaceutical Sciences" Mack Pub. Co., New Jersey (1991).
[0036] The compounds may be administered orally, topically, parenterally,
or
transdermally. The compounds are advantageously administered by injection or
by
intravenous infusion or suitable sterile solutions, or in the form of liquid
or solid doses via the
alimentary canal, or in the form of creams, ointments, patches, or similar
vehicles suitable for
transdermal applications. In some embodiments, doses of from about 0.001 1.,tg
to about 1 mg
per day of the compound are appropriate for treatment purposes. In some such
embodiments
an appropriate and effective dose may range from about 0.01 ng to about 1 mg
per day of the
compound. In other such embodiments an appropriate and effective dose may
range from
about 0.1 ng to about 500 ng per day of the compound. Such doses will be
adjusted
according to the type of disease or condition to be treated, the severity of
the disease or
condition, and the response of the subject as is well understood in the art.
The compound
may be suitably administered alone, or together with another active vitamin D
compound.
[0037] Compositions for use in the present technology include an effective
amount of
(20S)-2-Methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 and/or (20R)-2-
methylene-19-nor-22-dimethyl-la,25-dihydroxyvitamin D3 as the active
ingredient, and a
suitable carrier. An effective amount of a compound herein for use in
accordance with some
embodiments of the present technology will generally be a dosage amount such
as those
described herein, and may be administered topically, transdermally, orally,
nasally, rectally,
or parenterally.
[0038] The compounds of formula IIA, IIB, TIC and IID may be advantageously
administered in amounts sufficient to effect the differentiation of
promyelocytes to normal
macrophages. Dosages as described above are suitable, it being understood that
the amounts
given are to be adjusted in accordance with the severity of the disease, and
the condition and
response of the subject as is well understood in the art.
[0039] The compounds may be formulated as creams, lotions, ointments,
aerosols,
suppositories, topical patches, pills, capsules or tablets, or in liquid form
as solutions,
emulsions, dispersions, or suspensions in pharmaceutically innocuous and
acceptable solvent
13
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
or oils, and such preparations may contain, in addition, other
pharmaceutically innocuous or
beneficial components, such as stabilizers, antioxidants, emulsifiers,
coloring agents, binders
or taste-modifying agents.
[0040] The formulations of the present technology comprise an active
ingredient in
association with a pharmaceutically acceptable carrier therefore and
optionally other
therapeutic ingredients. The carrier must be "acceptable" in the sense of
being compatible
with the other ingredients of the formulations and not deleterious to the
recipient thereof.
[0041] Formulations of the present technology suitable for oral
administration may be
in the form of discrete units as capsules, sachets, tablets or lozenges, each
containing a
predetermined amount of the active ingredient; in the form of a powder or
granules; in the
form of a solution or a suspension in an aqueous liquid or non-aqueous liquid;
or in the form
of an oil-in-water emulsion or a water-in-oil emulsion.
[0042] Formulations for rectal administration may be in the form of a
suppository
incorporating the active ingredient and carrier such as cocoa butter, or in
the form of an
enema.
[0043] Formulations suitable for parenteral administration conveniently
comprise a
sterile oily or aqueous preparation of the active ingredient which is
preferably isotonic with
the blood of the recipient.
[0044] Formulations suitable for topical administration include liquid or
semi-liquid
preparations such as liniments, lotions, applicants, oil-in-water or water-in-
oil emulsions such
as creams, ointments or pastes; or solutions or suspensions such as drops; or
as sprays.
[0045] For nasal administration, inhalation of powder, self-propelling or
spray
formulations, dispensed with a spray can, a nebulizer or an atomizer can be
used. The
formulations, when dispensed, preferably have a particle size in the range of
10 to 100
microns.
[0046] The formulations may conveniently be presented in dosage unit form
and may
be prepared by any of the methods well known in the art of pharmacy. By the
term "dosage
unit" is meant a unitary, i.e., a single dose which is capable of being
administered to a patient
14
CA 2794006 2017-05-12
as a physically and chemically stable unit dose comprising either the active
ingredient as such
or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
EXAMPLES
Example 1: Synthesis of (20S)-2-methylene-19-nor-22-dimethyl-1a,25-
dihydroxyyitamin D3
[0048] Compounds of the present technology, including (20S)-2-methylene-19-
nor-
22-dimethyl-1a,25-dihydroxyvitamin D3, were prepared using the methods shown
in
Schemes 1-3. As shown in Scheme 2, compound 2 is obtained by ozonolysis of
vitamin D2
(compound 1) as described by Sicinski et al. (J. 3/led. Chem 41, 4662-4672,
1998), followed
by reduction with borohydride. Treatment of the dialcohol 2 with tosyl
chloride in pyridine
provides the tosylate compound 3. Compound 3 is protected by treatment with
triethylsilyl
triflate (TESOTf) and 2,6-lutidine in dichloromethane to give compound 4. The
tosylate of
compound 4 was displaced with cyanide in dimethyl sulfoxide (DMSO) to give
cyano
compound 5. Reaction of compound 5 with lithium diisopropyl amide (LDA) in
tetrahydrofuran (THF) and alkylation with methyl iodide provided compound 6,
which was
subsequently reduced with di isobutyl aluminum hydride (DIBAL) in
dichloromethane to
provide aldehyde 7.
[0049] Scheme 3 illustrates the conversion of compound 7 to the title
compound of
Formula HA (compound 14). First, the aldehyde 7 is reacted with
triethylphosphonoacetate 8
in the presence of LDA to provide alkene 9. Compound 9 was hydrogenated over
Pd/C in
methanol to give compound 10, and the latter compound was reacted with methyl
Grignard
reagent to give the tertiary alcohol, 11. Oxidation with
tetrapropylperruthenate in the
presence of N-methylmorpholine N-oxide, followed by protection of the
remaining alcohol
with TESOTf under the same conditions as before led to ketone 12. Compound 12
was
coupled with the A-ring phosphonium salt (compound H from Scheme 1) using
phenyl
lithium to produce compound 13, the silyl protected vitamin derivative (a
compound of
formula I and IA). Removal of all the silyl protecting groups was effected
with HF in
acetonitrile (ACN) to give compound 14 (a compound of formula I and IA). This
product
was fully characterized as described below.
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
Scheme 2
OH
11101 1.03, py, Me0H
___________________________________________ 1. Ilk
1 2. NaBH4
OH
1 1 2
HO 11111
TsCI, py
Y
ON cl...c ,,
...,NaCN, DM SO Oa. OTs
, TESOTf ,õ
2,6-lutidine OlioIS
CH2Cl2 OTs
OTES OTES OH
4
3
1. LDA, THF
2. CH3I
V
_. 0
ON
Oil DIBAL, CH2Cl2
_______________________ >
Oil
OTES OTES
6 7
16
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
Scheme 3
LDA, THF
0
(Et0)2P(0)CH2000Et
OTES 8 OTES
7 9
H2, Pd/C, Me0H
OTES OH
CH3MgBr 0
1.TPAP, NMO, Et20
CH2Cl2
0 OH OH
2. TESOTf,
2.6-lutidine,
12 CH2CI2 11 10
TBS04,
A
Ph Ph
OTBS
OTES OH
1. HF, MeCN,THF
14
TBSO\'µ 13 OTBS HOS OH
(8S,205)-Des-A,B-20-(hydroxymethyl)-Dregnan-8-ol (2)
[0050] Ozone was passed through a solution of vitamin D2 1 (5g, 12.6 mmol)
and
pyridine (5 mL, 4.89 g, 62 mmol) in methanol (400 mL) at -78 C. When the
reaction mixture
turned deep blue it was flushed with oxygen for 15 min to remove the residual
ozone and
17
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
then it was treated with NaBH4 (1.5 g, 40 mmol). After 15 min the second
portion of NaBH4
(1.5 g, 40 mmol) was added and the mixture was allowed to warm to room
temperature. The
third portion of NaBH4 (1.5 g, 40 mmol) was added and the reaction mixture was
stirred for
18 hours. The reaction was quenched with water, concentrated under reduced
pressure and
extracted with dichloromethane. The combined organic phases were washed with
1M
aqueous HC1, saturated aqueous NaHCO3 and dried (Na2SO4) and concentrated. The
residue
was purified by column chromatography on silica gel (30%, then 50% ethyl
acetate/hexane)
to give the diol 2 (2.61 g, 49%) as colorless crystals.
m.p. 107 C (from ethyl acetate/hexane); [a]r) +32.9 (c 1.0, CHC13); 1H NMR
(500 MHz,
CDC13) 6 4.07 (1H, d, J = 2.5 Hz), 3.62 (1H, dd, J = 10.5, 3.2 Hz), 3.37 (1H,
dd, J = 10.5, 6.8
Hz), 1.98 (1H, m), 1.80 (3H, m), 1.02 (3H, d, J = 6.6 Hz), 0.94 (3H, s); 13C
NMR (125 MHz,
CDC13) 6 69.21, 67.81, 52.91, 52.34, 41.84, 40.20, 38.22, 33.55, 26.64, 22.55,
17.38, 16.60,
13.56; MS (El) in/z 212 (1, M-1), 194 (28, Mt H20), 179 (29), 163 (22), 147
(15), 135 (42),
125 (48), 111 (100), 97 (51); exact mass calculated for C111-1220 (MtH20)
194.1671, found
194.1673.
(8S,20S)-Des-A,B-20-1(p-toluenesulfonyboxylmethvl-pre2nan-8-ol (3)
[0051] A precooled (-20 C) solution of tosyl chloride (0.9 g, 4.73 mmol)
in pyridine
(2 mL) was added to a mixture of the diol 2 (0.52 g, 2.45 mmol) in dry
pyridine (5 mL) at -20
C. The reaction mixture was stirred for 3 h at -20 C, then it was warmed to 0
C and stirred
for 18 h. The mixture was pulled into a saturated aqueous Cu504 solution and
extracted with
dichloromethane. Combined organic phases were washed with a saturated aqueous
Cu504
solution and dried (Na2504) and concentrated. The residue was purified by
column
chromatography on silica gel (20% ethyl acetate/hexane) to afford of tosylate
3 (0.86 g, 96%
yield) as colorless crystals.
m.p. 95 C (from ethyl acetate/hexane); [a]n +17.4 (c 1.0, CHC13); 1H NMR (400
MHz,
CDC13) 6 7.77 (2H, d, J = 8.2 Hz), 7.34 (2H, d, J = 8.2 Hz), 4.06 (1H, s),
3.94 (1H, dd, J =
9.2, 3.1 Hz), 3.80 (1H, dd, J = 9.2, 6.2 Hz), 2.44 (3H, s), 1.90 (1H, m), 1.78
(2H, m), 0.95
(3H, d, J = 6.6 Hz), 0.88 (3H, s); 13C NMR (100 MHz, CDC13) 3 144.59, 133.01,
129.73,
127.86, 75.56, 68.98, 52.18, 41.81, 40.00, 35.66, 33.50, 26.36, 22.40, 21.60,
17.29, 16.69,
13.43; MS (El) nez 367 (6, MI-1-), 348 (5, M - H20), 307 (2), 194 (18), 179
(23), 150 (17),
135 (16), 125 (34), 111 (100), 91 (50); MS (ES1) m/z 389 (100, [M+Na]1), 755
(90,
18
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
[2M+Na]), 1121 (60, [3M+Na]1); exact mass (ESI) calculated for C20H3004SNa
[M+Na]1
389.1763, found 389.1758.
(8S,20S)-Des-A,B-8-r(triethylsilyl)oxyl-20-[(p-toluenesulfonyl)oxylmethyl-
pre2nane (4)
[0052] Triethylsilyl trifluoromethanesulfonate (0.6 mL, 0.70 g, 2.65 mmol)
was
added to a solution of the tosylate 3 (0.65 g; 1.78 mmol) and 2,6-lutidine
(0.3 mL, 0.28 g,
2.58 mmol) in dichloromethane (6 mL) at 0 C. The reaction mixture was stirred
for 15 min
and it was diluted with dichloromethane. The organic phase was washed with
water, dried
(Na2SO4) and concentrated. The residue was purified by column chromatography
on silica
gel (20% ethyl acetate/hexane) to give the product 4 (0.84 g, 99% yield) as a
light yellow oil.
[a]p +20.6 (c 1.0, CHC13); 1FINMR (400 MHz, CDC13) 6 7.78 (2H, d, J = 8.2 Hz),
7.34 (2H,
d, J = 8.2 Hz), 4.01 (1H, d, J = 2.0 Hz), 3.96 (1H, dd, J = 9.2, 3.0 Hz), 3.79
(1H, dd, J = 9.2,
6.5 Hz), 2.45 (3H, s), 1.87 (1H, m), 0.94 (3H, d, J = 5.9 Hz), 0.93 (9H, t, J
= 7.9 Hz), 0.86
(3H, s), 0.54 (6H, q, J = 7.9 Hz); 13C NMR (125 MHz, CDC13) 6 144.55 (0),
133.10 (0),
129.73 (1), 127.91 (1), 75.76 (2), 69.11 (1), 52.70 (1), 52.36 (1), 42.12 (0),
40.39 (2), 35.72
(1), 34.47 (2), 26.52 (2), 22.88 (2), 21.63 (3), 17.56 (2), 16.76 (3), 13.46
(3), 6.91 (3), 4.89
(2); MS (El) m/z no M1, 319 (46), 291 (9), 265 (9), 246 (5), 217 (100), 189
(81), 161 (69),
133 (54), 103 (38), 94 (39); MS (ESI) m/z 503 (100, [M+Na]1), 983 (40,
[2M+Nan, 1463
(71, [3M+Na]1); exact mass (ESI) calculated for C26H4404SSiNa [M+Na]-
503.2627, found
503.2629.
(8S,20R)-Des-A,B-8-[(triethylsilyboxy1-20-(cyanomethyl)-pre2nane (5)
[0053] Sodium cyanide (2 g, 41 mmol) was added to a solution of tosylate 4
(0.84 g,
1.75 mmol) in dry DMSO (8 mL). The resulting mixture was stirred at 90 C for
3 h, then it
was cooled, diluted with water and extracted with ethyl acetate. Combined
organic phases
were dried (Na2SO4) and concentrated. The residue was purified by column
chromatography
on silica gel (10% ethyl acetate/hexane) to give the cyanide 5 (0.57 g, 97%
yield) as a
colorless oil.
[a]) +16.6 (c 1.0, CHC13); 1FINMR (400 MHz, CDC13) 64.04 (1H, d, J = 2.1 Hz),
2.34 (1H,
dd, J = 16.6, 3.7 Hz), 2.23 (1H, dd, J = 16.6, 7.0 Hz), 1.92 (1H, m), 1.13
(3H, d, J = 6.6 Hz),
0.942 (9H, t, J = 7.9 Hz), 0.921 (3H, s), 0.55 (6H, q, J = 7.9 Hz); 13C NMR
(125 MHz,
CDC13) 6 119.09 (0), 69.12 (1), 55.34 (1), 52.86 (1), 42.18 (0), 40.35 (2),
34.40 (2), 33.09 (1),
27.19 (2), 24.69 (2), 22.82 (2), 19.23 (3), 17.53 (2), 13.63 (3), 6.91 (3),
4.89 (2); MS (El) nilz
19
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
335 (10), 320 (3), 306 (100), 292 (28), 225 (7), 202 (20), 188 (10), 161 (17),
135 (14), 103
(55); exact mass calculated for C24137ONSi (M-1) 335.2644, found 335.2656.
(8S,20S)-Des-A,B-8- r(triethylsilyl)oxyl-20-(1 '-methyl-l'-cyano-ethyl)-
pre2nane (6)
[0054] n-Butyllithium (1.6 M in hexane, 3.4 mL, 5.4 mmol) was added to a
solution
of diisopropylamine (0.76 mL, 0.544 g, 5.4 mmol) in THF (1 mL) at 0 C. The
resulting
mixture was stirred at 0 C for 30 min, then it was cooled to -78 C and a
solution of cyanide
(0.45 g, 1.34 mmol) in THF (2 mL) was added. The mixture was stirred at -78 C
for 30
min and then iodomethane (0.9 mL, 2.04 g, 14.4 mmol) was added. The reaction
mixture was
stirred at -78 C for 1 h and then at room temperature for 1 h. It was
quenched with saturated
aqueous NH4C1 solution and extracted with ethyl acetate. Combined organic
phases were
washed with brine, dried (Na2SO4) and concentrated. The residue was purified
by column
chromatography on silica gel (10%, then 20% ethyl acetate/hexane) to give the
product 6
(0.49 g, 100% yield).
MD +34.5 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6' 4.04 (1H, d, J = 2.5 Hz),
1.37 (3H,
s), 1.28 (3H, s), 0.99 (3H, d, J = 6.9 Hz), 0.97 (3H, s), 0.95 (9H, t, J = 7.9
Hz), 0.55 (6H, q, J
= 7.9 Hz); 13C NMR (100 MHz, CDC13) 6 127.28 (0), 69.26 (1), 54.06 (1), 52.33
(1), 43.55
(0), 42.77 (1), 41.17 (2), 35.67 (0), 34.48 (2), 27.97 (2), 27.43 (3), 23.45
(2), 22.70 (3), 17.69
(2), 14.60 (3), 13.17 (3), 6.92 (3), 4.91 (2); MS (El) m/z 363 (28, M-1), 349
(14), 334 (100),
321 (65), 306 (27), 261 (11), 225 (27), 183 (14), 163 (36), 135 (47), 103
(99), 75(58); exact
mass calculated for C22H41ONSi (M-) 363.2957, found 363.2957.
(8S,20S)-Des-A,B-8- r(triethylsilyl)oxyl-20-(1'-methyl-l'-formyl-ethyl)-
pre2nane jfl
[0055] Diisobutylaluminium hydride (1.0 M in dichloromethane, 2.5 mL, 2.5
mmol)
was added to a solution of the compound 6 (0.49 g, 1.35 mmol) in
dichloromethane (3 mL) at
-10 C. The reaction mixture was stirred at -10 C for 1 hour, then it was
quenched with a
saturated aqueous sodium potassium tartrate solution (5 mL). The water phase
was extracted
with dichloromethane. Combined organic layers were washed with brine and dried
(Na2SO4)
and concentrated. The residue was purified by column chromatography on silica
gel (10%,
then 20% ethyl acetate/hexane) to give the aldehyde 7 (0.47 g, 95% yield) as
colorless
crystals. m.p. 71-72 C (Et0Ac); [cdp +12.8 (c 1.0, CHC13); 1H NMR (400 MHz,
CDC13) 6
CA 2794006 2017-05-12
9.48 (1H, s), 4.00 (1H, d, J = 2.2 Hz), 2.00 (1H, m), 0.95 (6H, s), 0.94 (9H,
t, J = 7.8 Hz),
0.94 (3H, d, J = 6.9 Hz), 0.93 (3H, s), 0.54 (6H, q, J = 7.8 Hz); 13C NMR (100
MHz, CDC13)
6 207.03 (1), 69.30 (1), 54.46 (1), 52.65 (1), 50.05 (0), 43.02 (0), 41.22
(2), 40.21 (1), 34.57
(2), 28.73 (2), 23.34 (2), 22.74 (3), 17.72 (2), 15.20 (3), 13.61 (3), 13.22
(3), 6.92 (3), 4.92
(2); MS (El) m/z 366 (3, M+), 337 (10), 323 (4), 295 (10), 281 (5), 253 (6),
239 (8), 225 (38),
203 (6), 186 (22), 163 (100), 135 (56), 103 (87), 75(63); exact mass (ESI)
calculated for
C22F14202SiNa [M+Nal 389.2852, found 389.2855.
(8S,20S)-Des-A,B-8-4(triethylsilyl)oxyl-20-(1'-dimethyl-3'-ethyloxycarbonyl-2'-
propeny1)-pregnane (9)
[0056] n-
Butyllithium (1.6 M in hexane, 1.1 mL, 1.76 mmol) was added to a solution
of diisopropylamine (0.24 mL, 0.172 g, 1.70 mmol) in dry THF (1mL) at 0 C.
After 30 min
the mixture was cooled to -10 C and triethylphosphonoacetate 8 (0.38 mL,
0.426 g, 1.9
mmol) was added. The reaction mixture was stirred at -10 C for 30 min and
then a solution
of aldehyde 7 (31.4 mg, 0.086 mmol) in anhydrous THF (1 mL + 0.5 mL) was added
via
cannula. The mixture was stirred under argon at -10 C for 1 h, then it was
heated to 37 C
for 2.5 h and later it was stirred at room temperature overnight.
Dichloromethane was added
and the organic phase was washed with water, dried (Na2SO4) and concentrated.
The product
TM
was purified on Sep-Pak cartridge (5g). The cartridge was washed with
hexane/ethyl acetate
(2%) to give 9 (34.1 mg, 91% yield) as a colorless oil. MD -4.6 (c 1.0,
CHC13); H NMR
(400 MHz, CDC13) 6 7.07 (1H, d, J = 16.0 Hz), 5.64 (1H, d, J = 16.0 Hz), 4.19
(2H, q, J = 7.1
Hz), 4.00 (111, d, J = 2.1 Hz), 2.00 (1H, m), 1.30 (3H, t, J = 7.1 Hz), 1.00
(3H, s), 0.98 (3H,
s), 0.94 (9H, t, J = 7.9 Hz), 0.93 (3H, s), 0.93 (3H, d, J = 8.0 Hz), 0.54
(6H, q, J = 7.9 Hz);
"C NMR (100 MHz, CDC13) 6 167.52 (0), 162.38 (1), 115.17 (1), 69.44 (1), 60.04
(2), 54.44
(1), 52.45 (1), 45.28 (1), 43.45 (0), 41.30 (2), 40.91 (0), 34.59 (2), 29.75
(2), 27.44 (3), 23.79
(2), 21.34 (3), 17.74 (2), 15.03 (3), 14.29 (3), 13.01 (3), 6.92 (3), 4.92
(2); MS (El) m/z 437
(4, W), 421 (4), 407 (43), 366 (5), 337 (5), 295 (42), 281 (13), 256 (42), 225
(18), 191
(27), 163 (100); MS (ESI) m/z 459 (81, [M+Na]+), 895 (75, [2M+Na]+), 1331 (94,
[3M+Na]4), exact mass (ESI) calculated for C26H4803SiNa [M+Na]+ 459.3270,
found
459.3254.
21
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
(8S,20S)-Des-A,B-20-(1'-dimethy1-3'-ethy1oxycarbonv1-propy1)-premn-8-o1 (10)
[0057] A solution of the ester 9 (34.1 mg, 0.078 mmol) in methanol (5 mL)
was
hydrogenated in the presence of 10% palladium on powdered charcoal (10 mg) at
room
temperature for 20 h. The reaction mixture was filtered through a Waters
silica Sep-Pak
cartridge (2 g), which was further washed with methanol. After removal of the
solvent the
ester 10 (24.0 mg, 95%) was obtained as a colorless oil. MD +7.1 (c 1.0,
CHC13); 1H NMR
(500 MHz, CDC13) 6 4.12 (2H, q, J = 7.1 Hz), 4.07 (1H, d, J = 2.1 Hz), 2.25
(2H, m), 2.10
(1H, m), 1.26 (3H, t, J = 7.1 Hz), 0.99 (3H, s), 0.92 (3H, d, J = 7.1 Hz),
0.91 (3H, s), 0.86
(3H, s); 13C NMR (125 MHz, CDC13) 6 174.60 (0), 69.47 (1), 60.23 (2), 53.30
(1), 51.90 (1),
43.53 (0), 43.14 (1), 40.90 (2), 36.34 (0), 36.25 (2), 33.57 (2), 29.94 (2),
29.44 (2), 27.49 (3),
26.21 (3), 23.36 (2), 17.48 (2), 14.89 (3), 14.22 (3), 13.08 (3); MS (El) m/z
325 (3, MH+),
306 (5), 278 (8), 261 (7), 224 (7), 181 (15), 163 (56), 143 (100), 111 (76),
97(62); MS (ESI)
in/z 347 (85, [M+Na]'), 671 (9, [2M+Nar), exact mass calculated for naC201-
13603Na
[M+Nal+ 347.2562, found 347.2556.
(8S,20S)-Des-A,B-22-dimethyl-cholestan-8,25-diol (11)
[0058] Methylmagnesium bromide (3.0 M solution in diethyl ether, 654, 0.195
mmol) was added to a solution of the ester 10 (24 mg, 0.074 mmol) in anhydrous
diethyl
ether (1.8 mL) at 0 C. The reaction mixture was stirred at 0 C for 2 h and
then at room
temperature for 18 h. It was quenched with saturated aqueous NRIC1 solution,
extracted with
ethyl acetate, dried (Na2SO4) and concentrated. The residue was applied to a
Waters silica
Sep-Pak cartridge (5 g). Elution with ethyl acetete/hexane (1:1) gave the diol
11(19.2 mg,
84%). [a]li, +4.8 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6 4.07 (1H, d, J =
2.1 Hz), 2.10
(1H, m), 1.21 (6H, s), 0.99 (3H, s), 0.91 (3H, s), 0.90 (3H, d, J = 8.2 Hz),
0.84 (3H, s); 13C
NMR (100 MHz, CDC13) 6 71.19 (0), 69.51 (1), 53.43 (1), 51.91 (1), 43.51 (0),
42.65 (1),
40.91 (2), 37.59 (2), 36.29 (2), 36.24 (0), 33.55 (2), 29.89 (2), 29.23 (3),
29.17 (3), 28.04 (3),
26.29 (3), 23.38 (2), 17.49 (2), 14.87 (3), 13.10 (3); MS (El) m/z no M+, 292
(5), 259 (2), 223
(3), 205 (7), 181 (8), 163 (28), 129 (25), 111 (100), 95 (23); MS (ESI) ni/z
333 (95,
[M+Na]+), 643 (11, [2M+Na]+), exact mass (ESI) calculated for naC20H3802Na
[M+Na]+
333.2770, found 333.2774.
22
CA 2794006 2017-05-12
(20S)-Des-A,B-22-dimettry1-25-1(triethylsilyl)oxyl-cholestan-8-one (12)
[0059] Molecular sieves A4 (100 mg) were added to a solution of 4-
methylmorpholine oxide (150 mg, 1.28 mmol) in dichloromethane (600 [tL). The
mixture
was stirred at room temperature for 15 mm and tetrapropylammonium perruthenate
(8 mg,
22.8 l_tmol) was added, followed by a solution of diol 11 (19 mg, 0.061 mmol)
in
dichloromethane (400 + 200 4). The resulting suspension was stirred at room
temperature
TM
for 1 h. The reaction mixture was filtered through a Waters silica Sep-Pak
cartridge (2 g) that
was further washed with ethyl acetate. After removal of the solvent the ketone
(19 mg) was
obtained as a colorless oil.
Triethylsily1 trifluoromethanesulfonate (20 4, 23 mg, 0.088 mmol) was added
dropwise to a
solution of the ketone (19 mg, 0.062 mmol) and 2,6-lutidine (60 4, 55 mg,
0.515 mmol) in
dichloromethane (1.2 mL) at -40 C. The reaction mixture was stirred at -40 C
for 15 min,
then it was diluted with dichloromethane and washed with water. The organic
layer was dried
TM
(Na2SO4) and concentrated. The residue was applied to a Waters silica Sep-Pak
cartridge (5
g). Elution with hexane/ethyl acetate (1%, then 2%) gave the protected ketone
12 (20.2 mg,
78% yield).
[a]p -19.2 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6 2.33 (1H, d, J = 11.5,
7.5 Hz), 2.24
(3H, m), 1.19 (6H, s), 0.95 (9H, t, J = 7.9 Hz), 0.95 (3H, d, J = 6.9 Hz),
0.89 (3H, s), 0.84
(3H, s), 0.71 (3H, s), 0.56 (6H, q, J = 7.9 Hz); 13C NMR (100 MHz, CDC13) 6
212.46 (0),
73.40 (0), 61.73 (1), 53.18 (1), 51.09 (0), 43.36 (1), 41.08 (2), 39.48 (2),
38.77 (2), 36.15 (0),
35.76 (2), 30.76 (2), 29.87 (3), 27.70 (3), 26.24 (3), 23.94 (2), 19.96 (2),
14.72 (3), 12.87 (3),
7.14 (3), 6.81 (2); MS (El) m/z no M4, 407 (10), 393 (28), 364 (11), 294 (12),
273 (10), 173
(48), 163 (28), 111(100); MS (ESI) m/z 445 (8, [M+Na]1), exact mass (ESI)
calculated for
C26H5002SiNa [M+Na]f 445.3478, found 445.3486.
(20S)-2-Methylene-19-nor-22-dimethyl-la,25-dihydroxyvitamin D3 (14)
[0060] Phenyllithium (1.83 M in di-n-buthylether, 0.1 mL, 0.183 mmol) was
added to
a stirred solution of the phosphine oxide H (110 mg, 0.189 mmol) in anhydrous
THF (1 mL)
at -30 C. After 30 min the mixture was cooled to -78 C and a precooled
solution of the
ketone 12 (20 mg, 47.4 1..anol) in anhydrous THF (200 + 100 4) was added. The
reaction
mixture was stirred under argon at -78 C for 4 hours and then at +4 C for 19
h. Ethyl
acetate was added and the organic phase was washed with brine, dried (Na2SO4)
and
T4
concentrated. The residue was applied to a Waters silica Sep-Pak cartridge (5
g). The
23
CA 2794006 2017-05-12
cartridge was washed with hexane and ethyl acetate/hexane (1:99) to give the
crude product.
The vitamin was further purified by straight phase HPLC [9.4 x 250 mm Zorbax
Silica
column, 4 mL/min, hexane/2-propanol (0.1%) solvent system, R, = 3.4 min.] to
give the pure
protected compound 13 (33.83 mg, 91% yield).
UV (in hexane) Xtriax 263.5, 253.5, 245.5 nm; 1HNMR (400 MHz, CDC13) 6 6.22
(1H, d, J =
11.1 Hz, 6-H), 5.85 (1H, d, J = 11.1 Hz, 7-H), 4.97 (I H, s, =CH2), 4.92 (1H,
s, =CH2), 4.43
(2H, m, 113-H and 3a-H), 2.81 (1H, dm, J = 12.6 Hz), 2.52 (1H, dd, J = 13.3,
5.9 Hz, 10a-H),
2.47 (1H, dd, J = 12.6, 4.5 Hz, 4a-H), 2.34 (1H, dd, J = 13.3, 2.8 Hz, 1013-
H), 2.18 (1H, dd, J
= 12.6, 8.3 Hz, 413-H), 2.09 (1H, m), 1.97 (2H, m), 1.19 (6H, bs, 26-H3, 27-
H3), 0.95 (9H, t, J
= 7.9 Hz), 0.93 (3H, d, J = 6.8 Hz, 21-H3), 0.897 (9H, s, t-BuSi), 0.868 (9H,
s, t-BuSi), 0.889
and 0.833 (each 3H, each s, 28-H3, 30-H3), 0.62 (3H, s, 18-H3), 0.57 (6H, q, J
= 7.9 Hz),
0.080 (3H, s, SiMe), 0.068 (3H, s, SiMe), 0.049 (3H, s, SiMe), 0.027 (3H, s,
SiMe); 13C
NMR (100 MHz, CDC13) 6 152.98 (0, C-2), 141.40 (0, C-8), 132.77 (0, C-5),
122.46 (1, C-6),
116.43 (1, C-7), 106.25 (2, =CH2), 73.52 (0, C-25), 72.53 and 71.64 (each 1, C-
1, C-3), 56.02
(1), 52.84 (1), 47.60 (2), 46.96 (0, C-13), 44.18 (1), 41.14 (2), 38.84 (2),
38.57 (2), 36.23 (0,
C-22) , 35.85 (2), 31.28 (2), 29.91 and 29.86 (each 3, C-26, C-27), 28.84 (2),
27.75 (3),
26.22 (3), 25.84 (3), 25.78 (3), 23.53 (2), 23.17 (2), 18.25 (0), 18.17 (0),
14.70 (3), 12.53 (3),
7.15 (3), 6.84 (2), -4.86 (3), -5.10 (3); MS (EST) iii/z 809 (2, [M+Na]),
exact mass (EST)
calculated for C47H9003Si3Na [M+Na] 809.6096, found 809.6086.
[0061] The
protected compound 13 (33.82 mg, 43.0 mol) was dissolved in THF (4
mL) and acetonitrile (3 mL). A solution of aqueous 48% HF in acetonitrile (1:9
ratio, 4 mL)
was added at 0 C and the resulting mixture was stirred at room temperature
for 3 h.
Saturated aqueous NaHCO3 solution was added and the reaction mixture was
extracted with
dichloromethane. The combined organic phases were dried (Na2SO4) and
concentrated under
reduced pressure. The residue was diluted with 2 mL of hexane/ethyl acetate
(7:3) and
TM
applied to a Waters silica Sep-Pak cartridge (5 g). An elution with
hexane/ethyl acetate (7:3,
then 1:1) gave the crude product 14. The vitamin 14 was further purified by
straight phase
HPLC [9.4 x 250 mm Zorbax Silica column, 4 mL/min, hexane/2-propanol (85:15)
solvent
system, R, = 7.8 min.] and reverse phase HPLC [9.4 x 250 mm Zorbax RX-C18
column, 3
mL/min, methanol/water (85:15) solvent system, R, = 15.7 min.] to give the
pure compound
14 (14.336 mg, 75% yield).
24
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
UV (in Et0H) kmax 261.5, 252.0, 244.5 nm; 1H NMR (500 MHz, CDC13) 6 6.35 (1H,
d, J =
11.2 Hz, 6-H), 5.89 (1H, d, J = 11.2 Hz, 7-H), 5.10 (1H, s, =CH2), 5.08 (1H,
s, =CH2), 4.48
(2H, m, 113-H and 3a-H), 2.84 (1H, dd, J = 13.0, 4.3 Hz, 1013-H), 2.80 (1H,
dd, J = 13.3, 4.1
Hz, 9I3-H), 2.56 (1H, dd, J = 13.4, 3.3 Hz, 4a-H), 2.32 (1H, dd, J = 13.4, 6.1
Hz, 413-H), 2.28
(1H, dd, J = 13.0 Hz, 8.4 Hz, 10a-H), 2.08 (1H, m), 1.21 (6H, s, 26-H3, 27-
H3), 0.92 (3H, d, J
= 7.0 Hz, 21-H3), 0.91 and 0.84 (each 3H, each s, 28-H3, 30-H3), 0.62 (3H, 18-
H3); 13C NMR
(125 MHz, CDC13) 6 151.97 (0, C-2), 143.44 (0, C-8), 130.52 (0, C-5), 124.23
(1, C-6),
115.65 (1, C-7), 107.71 (2, =CH2), 71.79 and 70.63 (each 1, C-1, C-3), 71.23
(0, C-25), 56.01
(1), 52.77 (1), 47.07 (0, C-13), 45.77 (2), 43.90 (1), 40.98 (2), 38.15 (2),
37.64 (2), 36.28 (0,
C-22), 36.00 (2), 31.20 (2), 29.23 and 29.20 (each 3, C-26, C-27), 29.02 (2),
27.77 (3), 25.97
(3), 23.55 (2), 23.22 (2), 14.71 (3), 12.59 (3); MS (El) Tn/z 444 (30, Mt),
426 (7, Mt- H20),
411 (2), 341 (4), 315 (20), 297 (10), 269 (12), 247 (20), 223 (4), 192 (4),
175 (6), 161 (14),
135 (40), 111 (56), 91 (100), 69(24); MS (ESI) m/z 467 (49, [M+Na]+), 911 (11,
[2M+Na]),
exact mass (EST) calculated for C29H4803Na [M+Na]+ 467.3501, found 467.3507.
Example 2: Synthesis of (20R)-2-methylene-19-nor-22-dimethyl-la,25-
dihydroxyyitamin D3
[0062] Compounds
of the present technology, including (20R)-2-methylene-19-nor-
22-dimethyl-la,25-dihydroxyvitamin D3, were prepared using the methods shown
in
Schemes 4-6. As shown in Scheme 4, compound 4 is obtained by the same steps
shown in
Scheme 2 and described in Example 1. Komblum oxidation of tosylate 4 with
sodium
bicarbonate in DMSO provided aldehyde 15. Compound 15 was epimerized at
position 20
by treatment with tetrabutylammonium hydroxide to give compound 16 and reduced
with
sodium borohydride to give a mixture of diastereomers, from which compound 17,
with the
20R stereochemistry, was isolated.
[0063] As shown in Scheme 5, compound 17 was subjected to an analogous
series of
synthetic steps to those shown in Schemes 2 and 3 to provide compound 25, the
20R
diastereomer of compound 11. Likewise, as shown in Scheme 6, compound 25 was
subjected
to the same series of oxidation, protection, triethylphosphonoacetate
condensation and
deprotection steps as compound 11 in Scheme 3, to provide compound 28, (20R)-2-
m ethyl en e-19-nor-22-dim ethyl -1(1,25 -di hydroxyvitamin D3. This product
was fully
characterized as described below.
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
Scheme 4
OH
O61. 03, py, Me0H
I 2. NaBH4
OH
I 1 2
.0
HO" TsCI, py
cll
CHO .
OTs
TESOTf OTs
NaHCO3 2,6-lutidine
______________________ $6
, _____________________
DM SO CH2Cl2
OTES OTES OH
4 3
n-Bu4OH,
CH2Cl2
CHO cl.,c0HO6 J.
OH
NaBH4
. THF, Et0H +
OTES OTES
OTES
16 17 4
26
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
Scheme 5
OH
OTos
TsCI, Py NaCN
CN
DMSO
OTES OTES OTES
17 18 19
1. LDA,
THF
2. CH3I
ctV'CN
0 LDA, THF 5
DIBAL
(Eto)2P(o)cH2000Et CH2Cl2
OTES 8 OTES OTES
22 21 20
H2, Pd/C
Me0H
C) OH
0 CH3MgBr
Et20
OH OH
23 24
27
CA 02794006 2012-09-21
WO 2011/119610
PCT/US2011/029432
Scheme 6
OH
1.TPAP, NMO,
411111 CH2Cl2 OTES
2. TESOTf, 11110
2,6-lutidine,
OH
CH2Cl2
0
24 25
TBSO,
PhLi, THF,
OTBS Ph Ph
OH
OTES
11111111111
HF, MeCN,THF
.*
HO\µµ OH TBSO\µµ. OTBS
27 26
(8S,20S)-Des-A,B-8-1(triethylsilyl)oxy1-20-(formy1)-pre2nane (15)
[0064] Sodium bicarbonate (5 g, 59.5 mmol) was added to a solution of
tosylate 4
(2.31g, 4.81 mmol) in DMSO (15 mL). The reaction mixture was stirred at for 1
hour 15 min
120 'C and it was diluted with ethyl acetate. The organic phase was washed
with brine, dried
(Na2SO4) and concentrated. The residue was purified by column chromatography
on silica
gel (5% ethyl acetate/hexane) to give the product 5 (1.19 g, 76% yield) as a
colorless oil.
[1:4) +41.4 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6 9.58 (1H, d, J = 3.2
Hz), 4.06 (1H,
d, J = 2.4 Hz), 2.36 (1H, m), 1.09 (3H, d, J = 6.8, 3.0 Hz), 0.96 (3H, s),
0.94 (9H, t, J = 7.9
28
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
Hz), 0.56 (6H, q, J = 7.9 Hz); 13C NMR (125 MHz, CDC13) 6 205.40 (1), 69.01
(1), 52.38 (1),
51.69 (1), 49.17 (1), 42.64 (0), 40.49 (2), 34.54 (2), 26.20 (2), 23.28 (2),
17.58 (2), 13.89 (3),
13.32 (3), 6.92 (3), 4.90 (2); MS (El) tn/z 324 (5, M+), 295 (100, M- - Et0H),
281 (30), 246
(12), 191 (36), 175 (99), 135 (54), 103 (76); MS (ESI) m/z 671 (100,
[2M+Na]+), 995 (49,
[3M+Na]); exact mass calculated for C17H3102Si [M-Et] + 295.2093, found
295.2103.
(88,20R)-Des-A,B-8-[(triethylsilyboxy]-20-(hydroxymethyl)-pregnane (17)
[0065] Tetrabutylammonium hydroxide (40 wt. % solution in water, 4 mL, 3.98
g,
0.015 mol) was added to a solution of aldehyde 5 (0.97 g, 2.99 mmol) in
dichloromethane (20
mL). The reaction mixture was stirred for 18 hours at room temperature and it
was diluted
with dichloromethane. The organic phase was washed with water, dried (Na2SO4)
and
concentrated. The product was purified by column chromatography on silica gel
(3%, then
5% ethyl acetate/hexane) to give a mixture of isomers 16 (0.69 g, 71% yield).
Sodium
borohydride (0.2 g, 5.29 mmol) was added to a solution of aldehydes 16 (0.69
g, 2.13 mmol)
in THF (10 mL) and ethanol (10 mL). The reaction mixture was stirred for 45
min., quenched
with saturated NH4C1, extracted with ethyl acetate and dried (Na2SO4). The
residue was
purified by column chromatography on silica gel (4%, then 20% ethyl
acetate/hexane) to give
the pure isomer 17 (0.326 g, 47% yield) and a mixture of both isomers 17 and 4
(0.277 g,
40% yield).
[a]p +33.6 (c 1.0, CHCI3); 1H NMR (500 MHz, CDC13) 3 4.03 (1H, d, J = 2.5 Hz),
3.72 (1H,
dd, J = 10.7, 3.6 Hz), 3.44 (1H, dd, J = 10.7, 7.0 Hz), 0.95 (9H, t, J = 7.9
Hz), 0.94 (3H, d, J =
6.6 Hz), 0.93 (3H, s), 0.55 (6H, q, J = 7.9 Hz); 13C NMR (125 MHz, CDCI3) 6
69.25 (1),
66.84 (2), 53.01 (1), 41.91 (0), 40.20 (2), 37.49 (1), 34.58 (2), 26.73 (2),
22.81 (2), 17.67 (2),
16.58 (3), 13.88 (3), 6.93 (3), 4.91 (2); MS (El) rn/z 326 (7, M+), 311 (3, M+-
CH3), 297 (100,
MtEt), 283 (41), 265 (8), 225 (23), 193 (41), 177 (41), 135 (57), 103 (99); MS
(ESI) m/z 327
(100, [M+H]+); exact mass calculated for C17f13302Si [M-Et]+ 297.2250, found
297.2244.
(88,20R)-Des-A,B-8-[(triethylsilyboxy1-20-r(p-toluenesulfonyboxylmethyl-
pregnane (18)
[0066] A solution of tosyl chloride (0.38 g, 2 mmol) in pyridine (3 mL) was
transfered via cannula to a solution of alcohol 17 (0.326 g, 1 mmol) in
pyridine (5 mL) at -20
C. The reaction mixture was stirred at -20 C for 1 hour and then at +4 C
overnight. It was
diluted with methylene chloride, washed with a saturated aqueous solution of
Cu504 and
dried (Na2SO4). The residue was purified by column chromatography on silica
gel (5%, then
29
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
10% and 20% ethyl acetate/hexane) to give the tosylate 18 (427 mg, 89% yield)
as a colorless
oil.
[a]') +8.8 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6 7.78 (1H, d, J = 8.2 Hz),
7.34 (1H,
d, J = 8.2 Hz), 4.11 (1H, dd, J = 9.3, 3.4 Hz), 4.00 (1H, d, J = 2.0 Hz), 3.77
(1H, dd, J = 9.3,
7.4 Hz), 2.45 (3H, s), 0.93 (9H, t, J = 7.9 Hz), 0.87 (3H, d, J = 6.7 Hz),
0.81 (3H, s), 0.53
(6H, q, J = 7.9 Hz); 13C NMR (100 MHz, CDC13) 6 144.53 (0), 133.18 (0), 129.70
(1), 127.93
(1), 74.30 (2), 69.09 (1), 52.74 (1), 52.60 (1), 41.77 (0), 39.95 (2), 34.66
(1), 34.40 (2), 26.61
(2), 22.64 (2), 21.62 (3), 17.54 (2), 16.65 (3), 13.82 (3), 6.91 (3), 4.89
(2); MS (El) in/z 480
(18, M), 465 (2), 437 (14), 348 (2, M' - Et3SiOH), 309 (1, M' - CH3C6H4S03),
257 (91), 225
(23), 177 (100), 135 (19), 121 (24); MS (EST) m/z 503 (7, [M+Na]), 983 (4,
[2M+Na]),
1463 (10, [3M+Na]); exact mass calculated for C26H4404SSiNa [M+Na] 503.2627,
found
503.2639.
(8S,20S)-Des-A,B-8-r(triethylsilyl)oxyl-20-(cyanomethyl)-pregnane (19)
[0067] Sodium
cyanide (0.9 g, 18.4 mmol) was added to a solution of tosylate 18
(0.412 g, 0.858 mmol) in DMSO (5 mL). The resulting mixture was stirred at 90
C for 2 h,
then it was cooled, diluted with water and extracted with ethyl acetate.
Combined organic
phases were dried (Na2504) and concentrated. The residue was purified by
column
chromatography on silica gel (10% ethyl acetate/hexane) to give cyanide 19
(0.242 g, 85%
yield) as a colorless oil.
[a]p +17.3 (c 1.0, CHC13); 1H NMR (400 MHz, CDC13) 6 4.04 (1H, d, J = 2.2 Hz),
2.44 (1H,
dd, J = 16.7, 4.0 Hz), 2.38 (1H, dd, J = 16.7, 6.6 Hz), 1.06 (3H, d, J = 6.7
Hz), 0.94 (9H, t, J =
7.9 Hz), 0.91 (3H, s), 0.55 (6H, q, J = 7.9 Hz); 13C NMR (100 MHz, CDC13) 6
118.90 (0),
69.07 (1), 54.96 (1), 52.74 (1), 41.91 (0), 40.23 (2), 34.29 (2), 31.79 (1),
27.01 (2), 24.00 (2),
22.68 (2), 19.58 (3), 17.53 (2), 13.81 (3), 6.90 (3), 4.88 (2); MS (El) m/z
335 (3, 10, 320 (1,
M - Me) 306 (76, Mt Et), 292 (15), 271 (2), 225 (3), 202 (30), 161 (13), 103
(100), 75 (38);
MS (ESI) in/z 336 (7, [M+H] 358 (4,
[M+Na]'), 693 (100, [2M+Na]), 1028 (40,
[3M+Na]-); exact mass calculated for C18H32NOSi [M-Et] 306.2253, found
306.2253.
(8S,20R)-Des-A,B-8-[(triethylsilyboxy]-20-(1'-methyl-l'-cyano-ethyl)-
pregnane (20)
[0068] n-
Butyllithium (1.6 M in hexane, 2.4 mL, 3.8 mmol) was added to a solution
of diisopropylamine (0.54 mL, 0.384 g, 3.8 mmol) in THF (2 mL) at 0 C. The
resulting
mixture was stirred at 0 C for 30 min, then it was cooled to -78 C and a
solution of the
CA 2794006 2017-05-12
compound 19 (0.326 g, 0.973 mmol) in THF (2 mL) was added. The mixture was
stirred at -
78 C for 30 min and then iodomethane (1.2 mL, 2.73 g, 19.2 mmol) was added.
The reaction
mixture was stirred at -78 C 1 h and then at room temperature for 1 h. It was
quenched with
saturated aqueous NH4C1 solution and extracted with ethyl acetate. Combined
organic phases
were washed with brine, dried (Na2SO4) and concentrated. The residue was
purified by
column chromatography on silica gel (5%, then 10% ethyl acetate/hexane) to
give the product
20 (0.197 g, 56% yield).
[a]r) + 30.9 (c 1.0, CHCI3); 11-1NMR (400 MHz, CDC13) 6 4.06 (1H, d, J = 2.2
Hz), 1.30 (3H,
s), 1.26 (3H, s), 0.97 (3H, d, J = 7.1 Hz), 0.95 (9H, t, J = 7.9 Hz), 0.84
(3H, s), 0.55 (6H, q, J
= 7.9 Hz); 13C NMR (100 MHz, CDC13) 6 126.16 (0), 68.91 (1), 52.01 (1), 50.84
(1), 42.88
(0), 37.84 (1), 37.77 (2), 34.88 (2), 24.97 (3), 23.88 (3), 23.17 (2), 21.81
(2), 17.36 (2), 14.54
(3), 13.03 (3), 6.92 (3), 4.90 (2); MS (El) rn/z 363 (13, M+), 334 (72, Mt-
Et), 320 (12), 295
(4), 261 (4), 249 (15), 234 (29), 191 (100), 163 (72), 111 (81), 93 (28),
81(39), 57 (49); MS
(El) fez 363 (12, M1), 334 (71), 320 (12), 295 (4), 234 (28), 191 (100), 163
(71), 135 (42),
111 (80); MS (ES1) rn/z 364(11, [M+H]+), 749 (62, [2M+Na]1), 1113 (100,
[3M+Na+H]2+);
exact mass calculated for C22H42ONSi [M+H] 364.3031, found 364.3044.
(8S,20R)-Des-A,B-8-1(triethvIsilyl)oxyl-20-(1'-methyl-l'-formyl-ethyl)-
pregnane (21)
[0069]
Diisobutylaluminium hydride (1.0 M in dichloromethane, 3.1 mL, 3.1 mmol)
was added to a solution of the compound 20 (0.197 g, 0.543 mmol) in
dichloromethane (4
mL) at -10 C. The reaction mixture was stirred at -10 C for 1 hour, then it
was quenched
with a saturated aqueous sodium potassium tartrate solution (5 mL). The water
phase was
extracted with diehloromethane. Combined organic layers were washed with brine
and dried
(Na2SO4) and concentrated. The residue was purified on Sep-PakTM
cartridge (5g). The
cartridge was washed with hexane/ethyl acetate (9:1) to give the aldehyde 21
as colorless oil
(0.15 g, 75% yield).
[ab +35.0 (c 1.0, CHC13). 11-1 NMR (400 MHz, CDC13) 6 9.40 (1H, s), 4.04 (1H,
d, J = 2.2
Hz), 0.95 (6H, s), 0.94 (9H, t, J = 7.8 Hz), 0.85 (3H, d, J = 7.00 Hz), 0.85
(3H, s), 0.55 (6H,
q, J = 7.8 Hz); 13C NMR (100 MHz, CDC13) 5 207.49 (1), 68.91 (1), 51.96 (1),
50.79 (1),
50.68 (0), 42.89 (0), 38.34 (2), 34.88 (2), 33.78 (1), 23.18 (2), 22.13 (2),
19.41 (3), 18.09 (3),
17.40 (2), 14.48 (3), 12.29 (3), 6.92 (3), 4.90 (2); MS (El) in/z 366 (1, Mt),
337 (31, Mt-Et),
307 (37), 295 (12), 251 (13), 225 (30), 203 (22), 186 (9), 171 (14), 163 (74),
135 (43), 103
31
CA 2794006 2017-05-12
(100); MS (ESI) nilz 389 (29, [M+Na]), 755 (73, [2M+Na]+), 1121 (15, [3M+Naf
); exact
mass (ESI) calculated for C22H4202S1Na [M+Na] 389.2847, found 389.2838.
(88,20R)-Des-A,B-8-1(triethylsilyl)oxy1-20-(1'-dimethyl-3'-ethyloxycarbonyl-2'-
propeny1)-pregnane (22)
[0070] n-Butyllithium (1.6 M in hexane, 5.2 mL, 8.3 mmol) was added to a
solution
of diisopropylamine (1.2 mL, 0.840 g, 8.3 mmol) in dry THF (2 mL) at 0 C.
After 30 min
the mixture was cooled to -10 C and triethylphosphonoacetate 8 (1.9 mL, 2.13
g, 9.5 mmol)
was added. The reaction mixture was stirred at -10 C for 30 min and a
solution of the
aldehyde 21(0.15 g, 0.41 mmol) in anhydrous THF (5 mL + 3 mL) was added via
cannula.
The mixture was stirred under argon at -10 C for 1 h, then it was heated to
+37 C for 3 h
and later it was stirred at room temperature for 18 h. Dichloromethane was
added and the
organic phase was washed with water, dried (Na2SO4) and concentrated. The
product was
TM
purified on Sep-Pak cartridge (5g). The cartridge was washed with hexane/ethyl
acetate (2%,
then 3% and 5%) to give the product 22 (99 mg, 55% yield) as a colorless oil.
[alp +18.1 (c
1.0, CHC13); 11-1 NMR (400 MHz, CDC13) 6 6.92 (1H, d, J ¨ 15.9 Hz), 5.69 (1H,
d, J = 15.9
Hz), 4.19 (2H, m), 4.03 (1H, d, J = 2.0 Hz), 1.29 (3H, t, J = 7.1 Hz), 0.98
(3H, s), 0.96 (3H,
s), 0.94 (9H, t, J = 7.9 Hz), 0.81 (3H, d, J = 7.0 Hz), 0.80 (3H, s), 0.54
(6H, q, J = 7.9 Hz);
1/C NMR (100 MHz, CDC11) 6 167.19 (0), 159.65 (1), 117.69 (1), 69.04 (1),
60.07 (2), 52.08
(1), 50.18 (1), 42.83 (0), 41.16 (0), 38.53 (1), 38.19 (2), 35.00 (2), 24.64
(3), 23.30 (3), 22.14
(2), 17.49 (2), 14.50 (3), 14.29 (3), 13.02 (3), 6.94 (3), 4.93 (2); MS (El)
tn/z 436 (0.3, M+),
407 (3, M -Et), 334 (2), 286 (10), 257 (18), 229 (100), 206 (16), 191 (99),
163 (26), 142 (16);
MS (EST) in/z 459 (99, [M+Na]+), 896 (100, [2M+Na+H]2+), 1332 (47,
[3M+Na+H]2+), exact
mass (EST) calculated for C26H4803SiNa [M+Na]' 459.3265, found 459.3259.
(88,20R)-Des-A,B-20-(1'-dimethy1-3'-ethy1oxycarbonyl-propyll-pregnan-8-ol (23)
[0071] A solution of the ester 22 (99 mg, 0.23 mmol) in methanol (5 mL) was
hydrogenated in the presence of 10% palladium on powdered charcoal (10 mg) at
room
temperature for 20 h. The reaction mixture was filtered through a Waters
silica Sep-Pak
cartridge (2 g), which was further washed with methanol. After removal of the
solvent the
ester 23 (50.4 mg, 68%) was obtained as a colorless oil.
[cdo +15.3 (c 1.0, CHC13). IFI NMR (400 MHz, CDC13) 64.12 (2H, q, J = 7.1 Hz),
4.09 (1H,
s), 2.25 (3H, m), 1.26 (3H, t, J = 7.1 Hz), 0.85 (3H, s), 0.80 (3H, s), 0.79
(3H, d, J = 7.6 Hz),
0.78 (3H, s); 13C NMR (100 MHz, CDC13) 6 174.60 (0), 69.07 (1), 60.21 (2),
51.69 (1), 49.40
32
CA 2794006 2017-05-12
=
(1), 42.60 (0), 37.93 (2), 37.07 (1), 36.04 (0), 34.57 (2), 33.92 (2), 29.54
(2), 24.82 (3), 24.56
(3), 22.90 (2), 22.26 (2), 17.26 (2), 14.49 (3), 14.20 (3), 12.62 (3); MS (El)
m/z 324 (3, Mt),
278 (7), 261 (8), 224 (7), 210 (5), 181 (15), 163 (70), 143 (100), 129 (33),
111 (72), 97(44),
69 (48); MS (ES!) In/z 342 (100, [M+NH4D, 671 (11, [2M+Na]t), exact mass
calculated for
C20E13703 [M+1-1]' 325.2738, found 325.2727.
(8S,20R)-Des-A,B-22-dimethyl-cholestan-8,25-diol (24)
[0072] Methylmagnesium bromide (3.0 M solution in diethyl ether, 130
[tL, 0.39
mmol) was added to a solution of the ester 23 (50 mg, 0.154 mmol) in anhydrous
diethyl
ether (3 mL) at 0 C. The reaction mixture was stirred at 0 C for 2 h and
then at room
temperature for 18 h. It was quenched with a saturated aqueous NH4C1 solution,
extracted
with ethyl acetate, dried (Na2SO4) and concentrated. The residue was applied
to a Waters
silica Sep-Palkmcartridge (5 g). Elution with ethyl acetete/hexane (1:1) gave
the diol 24 (48
mg, 100%) as colorless crystals. m.p. 122-124 C (from ethyl acetate/hexane);
[at) +21.2 (c
0.988, CHC13). 1H NMR (400 MHz, CDC13) 6 4.10 (1H, d, J = 1.8 Hz), 1.21 (6H,
s), 0.85
(3H, s), 0.81 (3H, s), 0.78 (3H, d, J = 7.3 Hz), 0.76 (3H, s); 13C NMR (100
MHz, CDCI3) 6
71.15 (0), 69.13 (1), 51.71 (1), 49.44 (1), 42.62 (0), 38.06 (2), 37.73 (2),
36.96 (1), 35.90 (0),
34.17 (2), 33.92 (2), 29.24 (3), 29.15 (3), 25.38 (3), 24.81 (3), 22.94 (2),
22.36 (2), 17.27 (2),
14.50 (3), 12.62 (3); MS (El) m/z 292 (5, M F-H20), 223 (3), 205 (9), 163
(43), 149 (9), 135
(21), 129 (41), 111 (100), 95 (25), 81 (20); MS (ESI) rn/z 310 (84, [M]), 328
(88,
[M+NH4]), 643 (24, [2M+Na]t), exact mass (ES!) calculated for naC20H3802Na
[M+Na]'
333.2765, found 333.2764.
(20R)-Des-A,B-22-dimethy1-25-1(triethylsilyfloxyl-cholestan-8-one (25)
[0073] Molecular sieves A4 (100 mg) were added to a solution of 4-
methylmorpholine oxide (90 mg, 0.77 mmol) in dichloromethane (400 1..LL). The
mixture was
stirred at room temperature for 15 min and tetrapropylammonium perruthenate
(9.7 mg, 27.6
limo was added, followed by a solution of diol 24 (29.4 mg, 0.095 mmol) in
dichloromethane (300 + 100 1,LL). The resulting suspension was stirred at room
temperature
TM
for 1 h. The reaction mixture was filtered through a Waters silica Sep-Pak
cartridge(2 g) that
was further washed with ethyl acetate. After removal of the solvent the ketone
(29.5 mg) was
obtained as a colorless oil.
[0074] Triethylsilyl trifluoromethanesulfonate (30 1xL, 35.1 mg,
0.133 mmol) was
added dropwise to a solution of the ketone (29.2 mg, 0.095 mmol) and 2,6-
lutidine (40 L, 37
33
CA 2794006 2017-05-12
= ,
mg, 0.343 mmol) in dichloromethane (1.6 mL) at -50 C. The reaction mixture
was stirred at
-40 C for 15 min, then it was diluted with dichloromethane and washed with
water. The
organic layer was dried (Na2SO4) and concentrated. The residue was applied to
a Waters
TM
silica Sep-Pak cartridge (5 g). Elution with hexane/ethyl acetate (1%, then
2%) gave the
protected ketone 25 (34.4 mg, 86% yield).
[a]p -8.8 (c 1.0, CHC13). 'FINMR (400 MHz, CDC13) 6 2.44 (1H, dd, J = 11.5,
7.5 Hz), 1.20
(6H, s), 0.95 (9H, t, J = 7.9 Hz), 0.82 (3H, s), 0.79 (3H, d, J = 7.5 Hz),
0.78 (3H, s), 0.58 (3H,
s), 0.57 (6H, q, J = 7.9 Hz); 13C NMR (100 MHz, CDC13) 6 212.18 (0), 73.42
(0), 60.66 (1),
51.10 (0), 49.73 (1), 41.01 (2), 38.88 (2), 38.26 (1), 36.76 (2), 35.95 (0),
33.93 (2), 29.89 (3),
25.17 (3), 24.91 (3), 23.66 (2), 22.68 (2), 19.47 (2), 12.99 (3), 12.33 (3),
7.14 (3), 6.82 (2);
MS (El) tri/z no M', 407 (33), 393 (68), 364 (54), 323 (11), 293 (25), 253
(42), 173 (82), 163
(70), 111 (78), 107 (100); MS (ESI) rn/z 423 (27, [M-FH11), 445 (47, [M+Na]'),
867 (26,
[2M+Na]+), 1290 (8, [3M+Na+H]2+), exact mass (ESI) calculated for C26H5102Si
[M+H]
423.3653, found 423.3649.
(2010-2-Methylene-19-nor-22-dimethy1-111,25-dihydroxyvitamin D3 (27)
[0075]
Phenyllithium (1.70 M in di-n-buthylether, 105 4, 0.178 mmol) was added to
a stirred solution of the phosphine oxide H (73.6 mg, 0.126 mmol) in anhydrous
THF (500
4) at -30 C. After 30 mm the mixture was cooled to -78 C and a precooled (-
78 C)
solution of the ketone 25 (35 mg, 82.9 mop in anhydrous THF (400 + 300 !IL)
was added.
The reaction mixture was stirred under argon at -78 C for 4 hours and then at
+4 C for 19 h.
Ethyl acetate was added and the organic phase was washed with brine, dried
(Na2SO4) and
TM
concentrated. The residue was applied to a Waters silica Sep-Pak cartridge(5
g). The
cartridge was washed with hexane and ethyl acetate/hexane (1:99) to give the
crude product.
TM
The vitamin was further purified by straight phase HPLC [9.4 x 250 mm Zorbax
Silica
column, 4 mL/min, hexane/2-propanol (0.1%) solvent system, Rt = 3.2 min.] to
give the pure
protected compound 26 (51.09 mg, 78% yield).
UV (in hexane) kn., 262.5, 252.5, 244.5 nm; IFI NMR (400 MHz, CDC13) 6 6.22
(1H, d, J =
11.1 Hz, 6-H), 5.84 (1H, d, J = 11.1 Hz, 7-H), 4.97 (1H, s, =CH2), 4.92 (1H,
s, =CH2), 4.42
(2H, m, 113-H and 3a-H), 2.85 (1H, dd, J = 12.8, 3.6 Hz, 913-H), 2.52 (1H, dd,
J = 13.2, 6.0
Hz, 10a-H), 2.46 (1H, dd, J = 12.6, 4.3 Hz, 4a-H), 2.34 (1H, dd, J = 13.2, 2.7
Hz, 1013-H),
2.18 (1H, dd, J = 12.6, 8.4 Hz, 4I3-H), 1.96 (1H, m), 1.19 (6H, s, 26-H3, 27-
H3), 0.95 (9H, t, J
= 7.9 Hz), 0.897 (9H, s, t-BuSi), 0.866 (9H, s, t-BuSi), 0.80 and 0.77 (each
3H, each s, 28-H3,
30-H3), 0.79 (3H, d, J ¨ 8.2 Hz, 21-H3), 0.57 (6H, q, J = 7.9 Hz), 0.46 (3H,
s, 18-H3), 0.080
34
CA 2794006 2017-05-12
(3H, s, SiMe), 0.069 (3H, s, SiMe), 0.049 (3H, s, SiMe), 0.029 (3H, s, SiMe);
13C NMR (100
MHz, CDC13) 6 152.98 (0, C-2), 141.35 (0, C-8), 132.64 (0, C-5), 122.44 (1, C-
6), 115.77 (1,
C-7), 106.24 (2, =CH2), 73.51 (0, C-25), 72.50 and 71.64 (each 1, C-1, C-3),
55.06 (1), 49.61
(1), 47.59 (2), 46.71 (0, C-13), 38.92 (2), 38.55 (2), 38.29 (2), 38.09 (1),
35.96 (0, C-22) ,
34.08 (2), 29.93 and 29.88 (each 3, C-26, C-27), 28.93 (2), 25.84 (3), 25.77
(3), 25.25 (3),
25.02 (3), 23.05 (2), 22.68 (2), 22.63 (2), 18.26 (0), 18.17 (0), 12.81 (3),
12.44 (3), 7.16 (3),
6.84 (2), -4.86 (3), -4.91 (3), -5.08 (3); MS (ESI) nilz 809 (40, [M+Nar),
exact mass (ESI)
calculated for C47H9003Si3Na [M+Na]' 809.6091, found 809.6101.
[0076] The
protected compound 26 (50.94 mg, 64.8 mol) was dissolved in THF (5
mL) and acetonitrile (3 mL). A solution of aqueous 48% HF in acetonitrile (1:9
ratio, 4 mL)
was added at 0 C and the resulting mixture was stin-ed at room temperature
for 2 h.
Saturated aqueous NaHCO3 solution was added and the reaction mixture was
extracted with
dichloromethane. The combined organic phases were dried (Na2SO4) and
concentrated under
reduced pressure. The residue was diluted with 2 mL of hexane/ethyl acetate
(7:3) and
applied to a Waters silica Sep-Pak cartridge (5 g), An elution with
hexane/ethyl acetate (7:3,
then 1:1) gave the crude product 20. The vitamin 20 was further purified by
straight phase
TM
HPLC [9.4 x 250 mm Zorbax Silica column, 4 mL/min, hexane/2-propanol (85:15)
solvent
TM
system, R1 = 7.4 min.] and reverse phase HPLC [9.4 x 250 mm Zorbax RX-C18
column, 3
mL/min, methanol/water (85:15) solvent system, Rt = 13.3 min.] to give the
pure compound
27 (22.71 mg, 79% yield).
m.p. 154 C (from 2-propanol/hexane); UV (in Et0H) Xmax 261.0, 252.0, 244.0
nm; NMR
(500 MHz, CDC13) 6 6.35 (1H, d, J = 11.2 Hz, 6-H), 5.88 (1H, d, J = 11.2 Hz, 7-
H), 5.11 (1H,
s, =CH2), 5.08 (1H, s, =CH2), 4.48 (2H, m, 113-H and 3a-H), 2.86 (1H, dd, J =
13.0, 4.7 Hz,
1013-H), 2.84 (1H, m, 9f3-H), 2.56 (1H, dd, J = 13.3, 3.5 Hz, 4a-11), 2.33
(1H, dd, J = 13.3, 6.0
Hz, 413-H), 2.28 (1H, dd, J = 13.0 Hz, 8.4 Hz, 10a-H), 1.96 (2H, m), 1.88 (1H,
m), 1.21 (6H,
s, 26-H3, 27-H3), 0.83 and 0.78 (each 3H, each s, 28-H3, 30-H3), 0.79 (3H, d,
J = 7.4 Hz, 21-
H3), 0.48 (3H, 18-H3); 13C NMR (125 MHz, CD03) 8 151.98 (0, C-2), 143.27 (0, C-
8),
130.51 (0, C-5), 124.09 (1, C-6), 115.02 (1, C-7), 107.66 (2, =CH2), 71.74 and
70.51 (each 1,
C-1, C-3), 71.23 (0, C-25), 55.05 (1), 49.52 (1), 46.81 (0, C-13), 45.70 (2),
38.10 (2 x 2),
37.73 (1 and 2), 35.95 (0, C-22), 34.17 (2), 29.20 (3), 29.13 (3), 29.06 (2),
25.35 (3), 24.83
(3), 23.05 (2), 22.65 (2 x 2), 12.82 (3), 12.41 (3); MS (El) nt/z 444 (6, M+),
426 (3, M+- H20),
393 (2), 341 (2), 313 (6), 269 (5), 251 (6), 199 (6), 191 (15), 161 (10), 145
(19), 111 (43),
107 (100), 89 (80), 79 (78), 75 (43); MS (EST) nt/z 467 (100, [M+Na]), 911(55,
[2M+Na]),
CA 2794006 2017-05-12
1355 (15, [3M+Na]', exact mass (ESI) calculated for C29H4501Na [M+Nal+
467.3496, found
467.3483.
Example 3: Biolnical Activity
Vitamin D Receptor Bindin2
Test Material
Protein Source
[0077] Full-length recombinant rat receptor was expressed in E. coil
BL21(DE3)
Codon Plus R1L cells and purified to homogeneity using two different column
chromatography systems. The first system was a nickel affinity resin that
utilizes the C-
terminal histidine tag on this protein. The protein that was eluted from this
resin was further
TM
purified using ion exchange chromatography (S-Sepharose Fast Flow). Aliquots
of the
purified protein were quick frozen in liquid nitrogen and stored at -80 C
until use. For use in
binding assays, the protein was diluted in TEDK50 (50 mM Tris, 1.5 mM EDTA, pH
7.4, 5
mM DTT, 150 mM KC1) with 0.1% Chaps detergent. The receptor protein and ligand
concentration was optimized such that no more than 20% of the added
radiolabeled ligand
was bound to the receptor.
Study Drugs
[0078] Unlabeled ligands were dissolved in ethanol and the concentrations
determined using UV spectrophotometry (1,25(OH)2D3: molar extinction
coefficient =
18,200 and Xmaõ = 265 nm; Analogs: molar extinction coefficient 42,000 and
A,max = 252
nm). Radiolabeled ligand (3H-1,25(OH)2D3, ¨159 Cilmmole) was added in ethanol
at a final
concentration of 1 nM.
Assay Conditions
[0079] Radiolabeled and unlabeled ligands were added to 1001..iL of the
diluted
protein at a final ethanol concentration of < 10%, mixed and incubated
overnight on ice to
reach binding equilibrium. The following day, 100 uL of hydroxylapatite slurry
(50%) was
36
CA 2794006 2017-05-12
= .
added to each tube and mixed at 10-minute intervals for 30 minutes. The
hydroxylapaptite
was collected by centrifugation and then washed three times with Tris-EDTA
buffer (50 mM
TM
Tris, 1.5 mM EDTA, pH 7.4) containing 0.5% Titron X-100. After the final wash,
the pellets
TM
were transferred to scintillation vials containing 4 mL of Biosafe IT
scintillation cocktail,
mixed and placed in a scintillation counter. Total binding was determined from
the tubes
containing only radiolabeled ligand.
HL-60 Differentiation
Test Material
Study Drugs
[0080] The study drugs were dissolved in ethanol and the
concentrations determined
using UV spectrophotometry. Serial dilutions were prepared so that a range of
drug
concentrations could be tested without changing the final concentration of
ethanol (< 0.2%)
present in the cell cultures.
Cells
[0081] Human promyelocytic leukemia (HL60) cells were grown in RPMI-
1640
medium containing 10% fetal bovine serum. The cells were incubated at 37 C in
the
presence of 5% CO2.
Assay Conditions
[0082] HL60 cells were plated at 1.2 x 105 cells/mL. Eighteen hours
after plating,
cells in duplicate were treated with drug. Four days later, the cells were
harvested and a nitro
blue tetrazolium reduction assay was performed (Collins et al., J. Exp. Med.
(1979) 149:969-
974). The percentage of differentiated cells was determined by counting a
total of 200 cells
and recording the number that contained intracellular black-blue formazan
deposits.
Verification of differentiation to monocytic cells was determined by measuring
phagocytic
activity (data not shown).
37
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
In Vitro Transcription Assay
[0083] Transcription activity was measured in ROS 17/2.8 (bone) cells that
were
stably transfected with a 24-hydroxylase (240hase) gene promoter upstream of a
luciferase
reporter gene (Arbour et al., Analytical Biochem. (1998) 255(1):148-154).
Cells were given a
range of doses. Sixteen hours after dosing the cells were harvested and
luciferase activities
were measured using a luminometer. RLU = relative luciferase units.
Intestinal Calcium Transport and Bone Calcium Mobilization
[0084] Male, weanling Sprague-Dawley rats were placed on Diet 11(0.47% Ca)
diet
+ AEK oil for one week followed by Diet 11(0.02% Ca) + AEK oil for 3 weeks.
The rats
were then switched to a diet containing 0.47% Ca for one week followed by two
weeks on a
diet containing 0.02% Ca. Dose administration began during the last week on
0.02% calcium
diet. Four consecutive intraperitoneal doses were given approximately 24 hours
apart.
Twenty-four hours after the last dose, blood was collected from the severed
neck and the
concentration of serum calcium determined as a measure of bone calcium
mobilization. The
first 10 cm of the intestine was also collected for intestinal calcium
transport analysis using
the everted gut sac method.
Biological Activity Results
[0085] (20S)-2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 (MET-
1)
is approximately equally effective as 1,25-(OH)2D3 in binding to the
recombinant vitamin D
receptor as shown in Fig. 1 (Ki of 4 x 10-11M and 5 x 10-11 M respectively).
However, MET-
1 is 4 times more potent than 1,25-(OH)2D3 at inducing the differentiation of
HL-60 cells in
culture as shown in Fig. 2 (7 x 10-1 M and 3 x 10-9M respectively). MET-1 is
10 times as
potent in stimulating 24-0Hase gene expression in bone cells than 1,25-(OH)2D
as shown in
Fig. 3 (3 x 10-11M and 2>< 10-1 M respectively). By contrast, in vivo testing
demonstrated
that MET-1 is 20 times less active than 1,25-(OH)2D3 on bone calcium
mobilization (Fig. 4),
and noticeably less active than 1,25-(OH)2D3 in causing intestinal calcium
transport (Fig. 5).
[0086] (20R)-2-methylene-19-nor-22-dimethyl-1a,25-dihydroxyvitamin D3 (MET-
2)
is equally effective as 1,25-(OH)2D3 in binding to the recombinant vitamin D
receptor as
shown in Fig. 6 (both display a Ki of 5 x 10-11M). MET-2 is 3 times more
potent than 1,25-
38
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
(OH)2D3 at inducing the differentiation of HL-60 cells in culture as shown in
Fig. 7 (7 x 10-
10M and 3 x 10-9M respectively). However, MET-2 is about 3 times less potent
in stimulating
24-0Hase gene expression in bone cells than 1,25-(OH)2D as shown in Fig. 8 (3
x 10-11M
and 2 x 10-1 M respectively). In vivo testing demonstrated that MET-2 is 16
times less active
than 1,25-(OH)2D3 on bone calcium mobilization (Fig. 4), and noticeably less
active than
1,25-(OH)2D3 in causing intestinal calcium transport (Fig. 5).
[0087] Comparative Example: Table 1 shows biological data for 2-methylene-
19-
nor-lct,25-dihydroxyvitamin D3 and its 20R isomer in comparison to compounds
from the
present disclosure (MET-1 and MET-2). The former compounds differ from the
latter in that
they have two methyl groups attached to the position 21 carbon rather than two
hydrogens.
While binding of the vitamin D receptor and HL-50 differentiation is generally
within an
order of magnitude for each compound, the present compounds demonstrate
surprising and
unexpected effects on calcemic activity. Whereas the 2MD compounds show
extremely
potent net bone calcium mobilization activity ranging from 4.5 mg/dL in the
20R isomer to
9.3 mg/dL in the 20S isomer, the present MET compounds show virtually no
calcemic
activity. On the other hand, while the 2 MD compounds demonstrate intestinal
calcemic
activity lower than that of vehicle, but the present compounds show small but
significant ratio
of scrosal to mucosal calcium, i.e., 1.2 to 2.3 for MET-2 and MET-1,
respectively.
[0088] These properties illustrate that both compounds should be very
useful in the
treatment of diseases where a rise in serum calcium is not desirable. Thus,
these compounds
should find utility in the treatment of secondary hyperparathyroidism of
patients suffering
from chronic kidney failure because it is undesirable to elevate serum calcium
above normal
in these patients for fear of calcification of heart, aorta and other vital
organs while
suppressing parathyroid gland proliferation and transcription of the
preproparathyroid gene.
Likewise, these compounds should be useful in the treatment of malignancy such
as breast,
colorectal and prostate cancers, or in the treatment of autoimmune diseases
such as multiple
sclerosis, lupus, rheumatoid arthritis, type 1 diabetes, and inflammatory
bowel disease. They
should also be useful in preventing transplant rejection.
39
Table 1
0
N
Net o
,-,
Competitiv
Net Bone ,--,
HL-60 24-
0HaseIntestinal _
,--,
e VDR
Ca2+ ,--
Example* Where Side chain Differentiation(
Transcription( Ca2+ v:
Binding
Mobilization ,--,
EC50, nM) ECK nM)
(Ki, nM)
(mg/dL)1 Transport
(S/M)2
Present
MET-1 0.04 0.7 0.03 0.4 2.3
¨i¨
c)
Present
0
MET-2 /"." 0.05 1 0.6
0.2 1.2 N)
-.3
I.0
OH Ø
=
0
0
01
N)
0
2MD3 US 5,843,928 "a.
srtrOHH
IV
I
0.12 4.2 454. -0.64
(20R) I -
0
l0
I
IV
H
2MD3 US 5,843,928
(20S).01-I 0.10 0.15 - 9.34
-0.94
*All compounds are 2-methylene-19-nor compounds
.:
iAt 780 pM dosage, except where indicated
n
,-i
2S/M = serosal Ca-Vmucosal Ca2+; at 780 pM dosage, except where indicated
3data from US 5,843,928 and,/ Med. Chem. 1998, 41, 4662
ci)
N.)
4At 260 pM dosage
.
.
-...
o
N.)
o
.6.
ci4
N.)
CA 02794006 2012-09-21
WO 2011/119610 PCT/US2011/029432
[0089] It is understood that the present technology is not limited to the
embodiments
set forth herein for illustration, but embraces all such forms thereof as come
within the scope
of the following claims.
41
